INTRODUCTION {#s1}
============

Cervical cancer is the second most common type of cancer affecting women worldwide and has an annual incidence of 530,000 new cases. Although current standard treatments for invasive cervical cancer are potentially curative, a significant number of patients develop recurrence and die of disease progression, with approximately 250,000 deaths being reported globally each year \[[@R1]\].

The identification of new prognostic factors for cervical cancer will improve our understanding of cervical cancer biology, contribute to the stratification of patients into risk groups, and identify those at a high risk of recurrence after the standard initial treatment.

Platelet count alterations including the platelet count and platelet-lymphocyte ratio (PLR) have recently been attracting attention as prognostic indicators in cancer patients \[[@R2]--[@R18]\]. The relationship between elevated platelet counts and malignancy was initially described in 1872 \[[@R19]\]. Since then, an increasing number of studies have reported thrombocytosis in patients with cancer from various origins, and demonstrated that it is associated with poor patient prognosis \[[@R20]--[@R23]\]. To the best of our knowledge, 13 studies have investigated the prognostic implications of thrombocytosis in cervical cancer patients, with about half suggesting that thrombocytosis is an independent prognostic factor in cervical patients (Table [1](#T1){ref-type="table"}). A recent study on ovarian cancer indicated that paraneoplastic thrombocytosis is due to the enhancements induced in hepatic thrombopoietin synthesis by tumor-derived IL-6. Moreover, the inhibition of thrombopoietin and IL-6 expression abrogated thrombocytosis in tumor-bearing mice and significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer \[[@R24]\]. Thus, thrombocytosis is now regarded not only as a prognostic indicator, but also as a potential therapeutic target in human cancers.

###### Summary of studies that investigated the relationship between platelet counts, platelet-lymphocyte ratios, and survival in patients with cervical cancer

  Reference                          No.   Stage     Treatment       Platelet or PLR   Cut-off value                                          Results                                                                                                                           Multivariate analysis
  ---------------------------------- ----- --------- --------------- ----------------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Hernandez et al. \[[@R2]\], 1992   113   I-IV      RT              Platelet          400 × 10^3^/μl                                         Independent prognostic indicator of 5-year survival                                                                               Yes
  Rodriguez et al. \[[@R3]\], 1994   219   IB        Surgery         Platelet          300 × 10^3^/μl                                         Independent prognostic indicator of 5-year survival                                                                               Yes
  Hernandez et al. \[[@R4]\],1994    623   IB        Surgery         Platelet          400 × 10^3^/μl                                         Not independent prognostic indicator of 5-year survival                                                                           Yes
  Lopes et al. \[[@R5]\], 1994       643   I-IV      Surgery or RT   Platelet          400 × 10^3^/μl                                         Prognostic indicator of 5-year survival                                                                                           No
  De Jonge et al. \[[@R6]\], 1999    93    IB        Surgery         Platelet          400 × 10^3^/μl                                         Not independent prognostic indicator of 5-year survival                                                                           yes
  Hernandez et al. \[[@R7]\],2000    291   IIB-IVA   RT              Platelet          400 × 10^3^/μl                                         Independent prognostic indicator of OS (patients negative pelvic nodes)                                                           Yes
  Gadducci et al. \[[@R8]\], 2010    46    IB2-IIB   Surgery         Platelet          272 × 10^3^/μl                                         Independent prognostic indicator of OS, but not of PFS                                                                            Yes
  Gadducci et al. \[[@R9]\], 2010    140   IB2-IIB   Surgery         Platelet          270 × 10^3^/μl                                         Not independent prognostic indicator of PFS and OS                                                                                Yes
  Qiu et al. \[[@R10]\], 2010        318   I-IV      NA              Platelet          400 × 10^3^/μl                                         Not prognostic indicator of OS                                                                                                    No
  Wang et al. \[[@R11]\], 2012       111   IB2-IIB   Surgery         Platelet          266 × 10^3^/μl                                         Not prognostic indicator of PFS and OS                                                                                            No
  Zhang et al. \[[@R12]\],2014       460   I-II      Surgery         PLR               150                                                    Not prognostic indicator of PFS and OS                                                                                            No
  Kawano et al. \[[@R13]\], 2015     286   IB-IVA    RT              Platelet          350 × 10^3^/μl                                         Independent prognostic indicator of OS                                                                                            Yes
  Xiao et al. \[[@R14]\], 2015       238   I-IV      CCRT            Platelet          200 × 10^3^/μl                                         Not prognostic indicator of PFS and OS                                                                                            No
  Zhao et al. \[[@R15]\], 2015       220   I-IIA     Surgery         Platelet          300 × 10^3^/μl                                         Not independent prognostic indicator of OS                                                                                        Yes
  Nakamura et al. \[[@R16]\], 2015   32    NA        CCRT            PLR               322                                                    Independent prognostic indicator of 200-day survival                                                                              Yes
  Zheng et al. \[[@R17]\], 2016      795   IA-IIA    Surgery         PLR               128.3                                                  Independent prognostic indicator of OS                                                                                            Yes
  Chen et al. \[[@R18]\], 2016       407   IB-IIA    Surgery         PLR               138.35 (PFS), 143.47 (OS)                              Independent prognostic indicator of PFS and OS                                                                                    Yes
  Present study, 2017                684   IA-IVA    Surgery or RT   Platelet, PLR     350 × 10^3^/μl (Platelet), 125.23 (PFS), 131.44 (OS)   Both factors are independent prognostic indicator of PFS and OS, Predictive value of platelet count is greater than that of PLR   Yes

RT, radiotherapy; CCRT, concurrent chemoradiotherapy; PLR, platelet-lymphocyte ratio; PFS, progression free survival; OS, overall survival; NA, not available.

As shown in Table [1](#T1){ref-type="table"}, [4](#T4){ref-type="table"} studies have investigated the prognostic implications of increased PLR in cervical cancer patients, with 3 studies suggesting that increased PLR is an independent predictor of survival. However, since most of the studies described above only included surgically-treated early-stage cervical cancer patients, the prognostic significance of PLR in cervical cancer remains unclear. Moreover, the clinical utilities of platelet counts and PLR have not yet been compared, and there is currently no information on how physicians may distinguish between platelet counts and PLR in the management of cervical cancer.

###### Clinicopathological characteristics of patients according to platelet counts and PLR ^1^

                                        All patients   Thrombocytosis   Normal platelet count          Elevated PLR   Normal PLR                                        
  ------------------------ ------------ -------------- ---------------- ----------------------- ------ -------------- ------------ ---------- ----- ------ ----- ------ ----------
  Age                      \< 50        268            39.2             52                      19.4   216            80.6                    123   45.9   145   54.1   
                           ≥ 50         416            60.8             35                      8.4    381            91.6         \< 0.001   140   33.7   276   66.3   0.0013
  Stage                    I-IIA        378            55.3             39                      10.3   339            89.7                    132   34.9   246   65.1   
                           IIB-IVB      306            44.7             48                      15.7   258            84.3         0.036      131   42.8   175   57.2   0.035
  Histology                SCC          511            74.7             63                      12.3   448            87.7                    189   37.0   322   63.0   
                           Non-SCC      173            25.3             24                      13.9   149            86.1         0.6        74    42.8   99    57.2   0.18
  Pelvic node metastasis   Negative     517            75.6             59                      11.4   458            88.6                    204   39.5   313   60.5   
                           Positive     167            24.4             28                      16.8   139            83.2         0.071      59    35.3   108   64.7   0.34
  Tumor size (mm)          \< 40        328            48.0             39                      11.9   289            88.1                    117   35.7   211   64.3   
                           ≥ 40         356            52.0             48                      13.5   308            86.5         0.53       146   41.0   210   59.0   0.15
  Treatment                Surgery      395            57.7             47                      11.9   348            88.1                    153   38.7   242   61.3   
                           Others ^2^   289            42.3             40                      13.8   249            86.2         0.45       110   38.1   179   61.9   0.86
  PLR                      \< 131.44    421            61.5             21                      5.0    400            95.0                                              
                           ≥ 131.44     263            28.5             66                      33.5   197            66.5         \< 0.001                             
  Platelet count (/μl)     \< 350,000   597            87.3                                                                                   197   33.0   400   67.0   
                           ≥350,000     87             12.7                                                                                   66    75.9   21    24.1   \< 0.001
  Total                                 684            100              87                      12.7   597            87.3                    263   38.5   421   61.5   

SCC, squamous cell carcinoma; PLR, platelet-lymphocyte ratio.

^1^ A PLR cut-off value of 131.44 was employed in this analysis.

^2^ Concurrent chemoradiotherapy, radiotherapy and chemotherapy.

###### Univariate and multivariate analyses for progression-free survival in cervical cancer patients

                                        Univariate analysis   Multivariate analysis ^1^   Multivariate analysis ^2^                                                      
  ------------------------ ------------ --------------------- --------------------------- --------------------------- ------ ------------ ---------- ------ ------------ ----------
  Age                      \< 50                                                                                                                                         
                           ≥ 50         1.3                   0.99--1.71                  0.058                       1.12   0.82--1.55   0.47       1.06   0.78--1.45   0.70
  Stage                    I-IIA                                                                                                                                         
                           IIB-IVB      3.87                  2.94--5.17                  \< 0.001                    2.16   1.48--3.17   \< 0.001   2.16   1.48--3.16   \< 0.001
  Histology                SCC                                                                                                                                           
                           Non-SCC      1.13                  0.84--1.5                   0.41                        1.86   1.34--2.54   \< 0.001   1.87   1.35--2.56   \< 0.001
  Pelvic node metastasis   Negative                                                                                                                                      
                           Positive     2.61                  2.01--3.38                  \< 0.001                    1.91   1.45--2.51   \< 0.001   2.00   1.52--2.64   \< 0.001
  Tumor size (mm)          \< 40                                                                                                                                         
                           ≥ 40         4.22                  3.63--7.09                  \< 0.001                    2.66   1.84--3.89   \< 0.001   2.65   1.83--3.86   \< 0.001
  Treatment                Surgery                                                                                                                                       
                           Others ^3^   1.94                  1.50--2.52                  \< 0.001                    0.95   0.68--1.37   0.80       0.99   0.70--1.39   0.93
  Platelet count (/μl)     \< 350,000                                                                                                                                    
                           ≥350,000     1.90                  1.35--2.62                  \< 0.001                    1.63   1.14--2.28   0.0077                         
  PLR                      \< 125.23                                                                                                                                     
                           ≥ 125.23     1.39                  1.07--1.79                  0.012                                                      1.31   1.01--1.70   0.044

SCC, squamous cell carcinoma; PLR, platelet-lymphocyte ratio; CI, confidence interval.

^1^ Multivariate analysis in which PLR is excluded from prognostic variables (platelet count is included).

^2^ Multivariate analysis in which platelet count is excluded from prognostic variables (PLR is included).

^3^ Concurrent chemoradiotherapy, radiotherapy and chemotherapy.

###### Univariate and multivariate analyses for overall survival in cervical cancer patients

                                        Univariate analysis   Multivariate analysis ^1^   Multivariate analysis ^2^                                                      
  ------------------------ ------------ --------------------- --------------------------- --------------------------- ------ ------------ ---------- ------ ------------ ----------
  Age                      \< 50                                                                                                                                         
                           ≥ 50         1.24                  0.93--1.68                  0.14                        0.97   0.70--1.37   0.88       0.93   0.67--1.30   0.69
  Stage                    I-IIA                                                                                                                                         
                           IIB-IVB      4.93                  3.58--6.91                  \< 0.001                    2.64   1.72--4.12   \< 0.001   2.64   1.72--4.11   \< 0.001
  Histology                SCC                                                                                                                                           
                           Non-SCC      1.14                  0.82--1.55                  0.43                        2.09   1.46--2.94   \< 0.001   2.05   1.44--2.88   \< 0.001
  Pelvic node metastasis   Negative                                                                                                                                      
                           Positive     2.50                  1.87--3.32                  \< 0.001                    1.77   1.31--2.39   \< 0.001   1.87   1.38--2.52   \< 0.001
  Tumor size (mm)          \< 40                                                                                                                                         
                           ≥ 40         5.03                  3.63--7.09                  \< 0.001                    2.78   1.83--4.30   \< 0.001   2.72   1.79--4.20   \< 0.001
  Treatment                Surgery                                                                                                                                       
                           Others 3     2.26                  1.70--3.01                  \< 0.001                    1.12   0.77--1.63   0.56       1.15   0.80--1.67   0.45
  Platelet count (/μl)     \< 350,000                                                                                                                                    
                           ≥350,000     1.93                  1.34--2.72                  \< 0.001                    1.56   1.06--2.24   0.025                          
  PLR                      \< 131.44                                                                                                                                     
                           ≥ 131.44     1.59                  1.20--2.11                  0.0012                                                     1.41   1.06--1.87   0.019

SCC, squamous cell carcinoma; PLR, platelet-lymphocyte ratio; CI, confidence interval.

^1^ Multivariate analysis in which PLR is excluded from prognostic variables (platelet count is included).

^2^ Multivariate analysis in which platelet count is excluded from prognostic variables (PLR is included).

^3^ Concurrent chemoradiotherapy, radiotherapy and chemotherapy.

In the present study, we first investigated the prognostic significance of elevated platelet counts and PLR in patients with FIGO stage IA-IVA cervical cancer. Then, we compared the clinical utilities of platelet counts and PLR for predicting the survival of patients with cervical cancer. Finally, we established a prognostic model using platelet counts and PLR to predict patient survival.

RESULTS {#s2}
=======

Prognostic significance of platelet counts {#s2_1}
------------------------------------------

The clinicopathological characteristics of patients according to platelet counts are shown in Table [2](#T2){ref-type="table"}. Among 684 patients, 87 (12.7%) had platelet counts equal to or greater than 350,000/ml (the thrombocytosis group) at the time of the initial diagnosis. Patients with thrombocytosis were significantly younger (*P \<* 0.001) and presented with a more advanced clinical stage (*P* = 0.036) than those without thrombocytosis. Thrombocytosis correlated with significantly shorter PFS (*P \<* 0.001) and OS (*P \<* 0.001) in the univariate analysis and Kaplan-Meier analysis (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, Figure [1A](#F1){ref-type="fig"}). In the multivariate analysis (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}), in addition to an advanced clinical stage, non-SCC histology, pelvic node metastasis, and larger tumor size, an elevated platelet count (\> 350,000/μl) was found to be an independent prognostic factor of PFS (HR, 1.63; 95% CI, 1.14--2.28; *P* = 0.0077) and OS (HR, 1.56; 95% CI, 1.06--2.24; *P* = 0.025).

![Clinical implications of platelet counts and PLR in cervical cancer patients (**A**) Significance of elevated platelet counts (Platelet count; ≥ 350,000/μl vs \< 350,000/μl). (i) Kaplan-Meier estimates of progression-free survival. (ii) Kaplan-Meier estimates of overall survival. (**B**) Significance of elevated PLR. (i) Kaplan-Meier estimates of progression-free survival (PLR; ≥ 125.23 vs \< 125.23). (ii) Kaplan-Meier estimates of overall survival (PLR; ≥ 131.44 vs \< 131.44).](oncotarget-08-55394-g001){#F1}

Prognostic significance of PLR {#s2_2}
------------------------------

ROC curves were described to select the optimal cut-off value for PLR ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The cut-off values of PLR for PFS and OS were 125.23 and 131.44, respectively. The clinicopathological characteristics of patients according to PLR are shown in Table [2](#T2){ref-type="table"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Among 684 patients, 300 (43.9%) and 263 (38.5%) displayed PLR equal to or greater than 125.23 and 131.44, respectively. Patients with elevated PLR were significantly younger (*P* = 0.0059, *P* = 0.0013) and presented with a more advanced clinical stage (*P* = 0.014, *P* = 0.035) than those with normal PLR. As shown in Figure [1B](#F1){ref-type="fig"}, elevated PLR correlated with significantly shorter PFS and OS (PFS: *P* = 0.0045, OS: *P* = 0.0022). In the multivariate analysis, in addition to an advanced clinical stage, non-SCC histology, pelvic node metastasis, and larger tumor size, elevated PLR remained an independent prognostic factor of PFS (Table [3](#T3){ref-type="table"}: HR, 1.31; 95% CI, 1.01--1.70; *P* = 0.044) and OS (Table [4](#T4){ref-type="table"}: HR, 1.41; 95% CI, 1.06--1.87; *P* = 0.019).

Comparison of utilities of platelet counts versus PLR {#s2_3}
-----------------------------------------------------

In order to compare the clinical utilities of platelet counts and PLR for predicting patient prognoses, ROC curves for platelet counts and PLR were generated and compared (Figure [2A](#F2){ref-type="fig"}). The area under the ROC curve (AUC) for predicting recurrence using platelet counts and PLR were 0.5941 (95% CI, 0.5448--0.6415) and 0.5331 (95% CI, 0.4833--0.5822), respectively. The AUC for predicting survival using platelet counts and PLR were 0.6139 (95% CI, 0.5552--0.6695) and 0.5468 (95% CI, 0.4889--0.6034), respectively. Platelet counts showed significantly greater AUC values than PLR for predicting recurrence (*p* = 0.018) and survival (*p* = 0.029).

![Comparison of clinical utilities of platelet counts and platelet-lymphocyte ratios\
(**A**) ROC curves for (i) recurrence and (ii) survival at 3 years for platelet counts and PLR. (**B**) Significance of PLR in patients without thrombocytosis (\< 350,000/μl). (i) Kaplan-Meier estimates of progression-free survival (PLR; ≥ 125.23 vs \< 125.23). (ii) Kaplan-Meier estimates of overall survival (PLR; ≥ 131.44 vs \< 131.44). (**C**) Significance of PLR in patients with thrombocytosis (≥ 350,000/μl). (i) Kaplan-Meier estimates of progression-free survival (PLR; ≥ 125.23 vs \< 125.23). (ii) Kaplan-Meier estimates of overall survival (PLR; ≥ 131.44 vs \< 131.44).](oncotarget-08-55394-g002){#F2}

Prognostic models using platelet counts and PLR {#s2_4}
-----------------------------------------------

In order to establish a model for the prediction of life expectancy, PFS and OS were first assessed according to platelet counts and PLR. As shown in Figure [2B](#F2){ref-type="fig"}, in patients without thrombocytosis, elevated PLR correlated with shorter PFS (*P* = 0.041) and OS (*P* = 0.017). In contrast, in patients with thrombocytosis, survival was not influenced by PLR, indicating that it does not provide any prognostic information in this patient population (Figure [2C](#F2){ref-type="fig"}).

Based on these results, we finally established a prognostic model in which patients were divided into 3 prognostic groups (Figure [3A(i)](#F3){ref-type="fig"}, [3B(i)](#F3){ref-type="fig"}): high-risk (patients with thrombocytosis regardless of PLR); intermediate-risk (patients with elevated PLR without thrombocytosis); low-risk (none of the above). As shown in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}, differential treatment outcomes were observed in association with the risk classifications. When PFS and OS were compared between the groups, patients in the high-risk group showed significantly lower PFS and OS rates than those in the intermediate-risk group (Figure [3A](#F3){ref-type="fig"} (ii): *P* = 0.021, 3B (ii): *P* = 0.018). Moreover, the PFS and OS rates of patients in the intermediate-risk group were significantly lower than those in the low-risk group (Figure [3A](#F3){ref-type="fig"} (ii): *P* = 0.045, 3B (ii): *P* = 0.043).

![Prognostic model using platelet counts and PLR\
(**A**) (i) Risk classification for progression-free survival. (ii) Kaplan-Meier estimates of progression-free survival based on risk classification. (**B**) (i) Risk classification for overall survival. (ii) Kaplan-Meier estimates of overall survival based on risk classification.](oncotarget-08-55394-g003){#F3}

DISCUSSION {#s3}
==========

In the present study, we showed that an elevated platelet count (≥ 350,000/μl) was an independent predictor of shorter PFS and OS in cervical cancer patients. These results are consistent with previous findings (Table [1](#T1){ref-type="table"}). Among our study population, 12.7% of patients displayed elevated platelet counts (≥ 350,000/μl), which correlated with a younger age and advanced clinical stage. We also observed elevated PLR (≥ 125.23 for PFS and ≥ 131.44 for OS) in approximately 40% of patients, and identified it as an independent predictor of shorter PFS and OS in cervical cancer patients. This result is also consistent with previous findings (Table [1](#T1){ref-type="table"}). However, since most of the studies that previously investigated the significance of increased PLR only included surgically-treated early-stage cervical cancer patients (Table [1](#T1){ref-type="table"}), the present study provides a novel insight into PLR in cervical cancer treatment: elevated PLR at the initial diagnosis is prognostically important regardless of the clinical stage and treatment modality. Moreover, our ROC analysis demonstrated, for the first time, that platelet counts are significantly superior to PLR for the prediction of patient prognoses. We consider this result to be clinically important because it suggests that platelet counts need to be preferentially examined in patients with cervical cancer.

There are currently no universally accepted risk classifications that may be applied to all cervical cancer patients: i.e. patients treated with surgery, definitive radiotherapy, and chemotherapy. Thus, the results of the present study may have valuable clinical implications. Since the present study includes stage IA-IVA cervical cancer patients treated with surgery, definitive radiotherapy, or chemotherapy, the prognostic model proposed herein may be applied to all cervical cancer patients. Moreover, our prognostic model requires only low-cost peripheral blood examinations to identify a group of patients at high risk of recurrence. As shown in Figure [3](#F3){ref-type="fig"}, we demonstrated that it was possible to divide patients into 3 prognostic groups using platelet counts and PLR: high-risk (patients with thrombocytosis regardless of PLR); intermediate-risk (patients with elevated PLR without thrombocytosis); low-risk (none of the above). This prognostic model may have advantages that are relevant to clinical practices: this simple model offers individualized survival estimates (Figure [3A](#F3){ref-type="fig"} (ii), 3B (ii)). In addition, this model may enable physicians to offer closer follow-ups for patients in the intermediate- and high-risk groups. The results shown in Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} also provide important information on the clinical applications of platelet counts and PLR: we recommend that platelet counts be initially examined for survival estimations in cervical cancer patients. PLR may then be evaluated in patients without thrombocytosis only because it did not provide prognostic information on patients with thrombocytosis.

Based on the poor prognosis of cervical cancer patients who display elevated platelet counts or PLR, novel treatment strategies need to be developed. The mechanisms responsible for increased platelet production in cervical cancer and subsequent increases in the aggressiveness of the disease remain poorly understood. However, theoretically, treatments targeting thrombopoiesis-stimulating cytokines or growth factors, their receptors, or their downstream effectors may exhibit therapeutic efficacy in cervical cancer patients displaying pretreatment thrombocytosis. In a previous study, the inhibition of thrombopoietin or IL-6 prevented the development of thrombocytosis in mice and significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer \[[@R24]\]. Thus, in order to obtain a clearer understanding of platelet count alterations and advance the development of novel treatments, further mechanistic investigations on cervical cancer are warranted.

The limitations of our study need to be addressed. The first limitation is that the present study was conducted at a single institution. We intend to verify our clinical findings in collaborative multi-institutional studies in the future. Another limitation is the retrospective nature of the present study. The significance of elevated platelet counts, PLR, and our prognostic model consisting of platelet counts and PLR need to be prospectively evaluated in future studies. The second limitation is the cut-off values used for thrombocytosis. In the present study, we defined elevated platelet counts as greater than or equal to 350,000/μl. The cut-off values for thrombocytosis in previous studies that investigate the significance of thrombocytosis in cervical cancer ranged between 200,000/μl and 400,000/μl, with 400,000/μl being the most popular cut-off value (Table [1](#T1){ref-type="table"}). However, most of the studies listed in Table [1](#T1){ref-type="table"} were from countries other than Japan. In studies on various malignant tumors from Japanese institutions, the cut-off values for thrombocytosis were lower: most studies employed a cut-off value between 22,000/μl and 370,000/μl to define thrombocytosis \[[@R23], [@R25]--[@R29]\]. The reason why a lower cut-off value was employed in studies from Japanese institutions currently remains unknown; however, the baseline platelet count in cancer patients may differ due to ethnicity. We also showed that patients with thrombocytosis were significantly younger (*P* \< 0.001) than those without thrombocytosis. This result is consistent with a recent finding on cervical cancer \[[@R17]\]. However, the reason for this phenomenon remains unknown. Thus, the optimal platelet threshold for diagnosing thrombocytosis and the underlying mechanisms responsible for the development of thrombocytosis need to be investigated in future studies.

In conclusion, thrombocytosis and elevated PLR at the time of the initial diagnosis were identified as independent predictors of PFS and OS in FIGO stage IA-IVA cervical cancer patients. Platelet counts were significantly superior to PLR for predicting patient prognoses. Our proposed prognostic model consisting of platelet counts and PLR offers individualized and accurate survival estimates.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Permission to proceed with data acquisition and analyses was obtained from the Institutional Review Board of Osaka University Hospital. A list of patients diagnosed with FIGO stage IA-IVA cervical cancer and treated at Osaka University Hospital between November 1993 and December 2011 was generated from our institutional tumor registry, and their clinical data were retrospectively analyzed. Patients who had been diagnosed with other types of cancers within the past 5 years, had a history of splenectomy, myeloproliferative disorders, or acute inflammatory disease were excluded. Of the 684 patients included in the present study, 286 had been examined in a previous clinical study \[[@R13]\].

Treatment and post-treatment follow-up {#s4_2}
--------------------------------------

Patients were treated in accordance with institutional treatment guidelines. Briefly, patients with FIGO stage IA2-IIB cervical cancer and younger than 70 years were treated with radical hysterectomy plus pelvic lymphadenectomy with or without adjuvant radiotherapy as described previously \[[@R30]\]. Adjuvant radiotherapy with or without platinum-based concurrent chemotherapy, was indicated when a patient\'s pathological report displayed any one of the following 'high-risk' prognostic factors: parametrial invasion, pelvic lymph node metastasis, or a positive surgical margin, or one of the following 'intermediate-risk' prognostic factors: deep stromal invasion, lymphovascular space invasion, or a large tumor (more than 4 cm in diameter), as reported previously \[[@R30]\]. Patients with FIGO stage III-IV disease, patients with FIGO stage I-II disease and older than 70 years, or patients with FIGO stage IA2-IIB disease and younger than 70 years who desired definitive radiotherapy rather than surgery were treated with definitive radiotherapy consisting of external beam radiation therapy followed by high-dose-rate intracavitary brachytherapy with or without platinum-based concurrent chemotherapy as described previously \[[@R31]\]. Patients with systemic disease were primarily treated with platinum-based chemotherapy as described previously \[[@R32], [@R33]\]. Follow-up examinations performed after the initial treatment were conducted by gynecological oncologists or/and radiation oncologists at regular intervals in an outpatient clinic, as reported previously \[[@R31], [@R34]\].

Definition of elevated platelet counts and PLR {#s4_3}
----------------------------------------------

During the period between the first presentation and the start day of the initial treatment, all patients underwent at least 2 blood tests including complete blood counts. Thrombocytosis was defined as platelet counts equal to or greater than 350,000/μl on at least 2 separate occasions, as described previously \[[@R13]\]. Elevated PLR for predicting progression-free survival (PFS) or overall survival (OS) were defined as PLR equal to or greater than 125.23 or 131.44, respectively ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The cut-off values for PLR were defined based on the maximum Youden index (i.e. sensitivity+specificity-1) in the time-dependent receiver operating characteristic (ROC) curve for PFS and OS, as reported previously \[[@R35], [@R36]\].

Statistical analysis {#s4_4}
--------------------

PFS was defined as the time from the date of therapy to the date of the first physical or radiographical evidence of disease progression. OS was defined as the time from the date of therapy to the date of death.

Time-dependent ROC curves were generated to evaluate the diagnostic performance of platelet counts and PLR for predicting recurrence or death at 3 years after the treatment. Differences in AUCs were analyzed according to the methods described in a previous study \[[@R37]\].

Continuous data were compared between the groups using the Student\'s *t*-test or Log-rank test, where appropriate. Frequency counts and proportions were compared between the groups using the chi-squared test or a two-tailed Fisher\'s exact test, where appropriate. The survival analysis was based on the Kaplan-Meier method and was compared by the Wilcoxon test. Cox\'s proportional hazards regression analysis was performed to identify significant independent prognostic factors for survival. *P*-values of \< 0.05 were considered to be significant. All analyses were performed using the software JMP Pro version 11.0 (SAS Institute, Cary, NC).

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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